World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0001918743
Reproduction Date:

Title: Propylthiouracil  
Author: World Heritage Encyclopedia
Language: English
Subject: Antithyroid agent, Carbimazole, Phenylthiocarbamide, Thyroid hormone, PROP
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
  • D
Legal status
  • (Prescription only)
Routes of
Pharmacokinetic data
Bioavailability 80%-95%
Metabolism ?
Biological half-life 2 hours
Excretion ?
CAS Registry Number  Y
ATC code H03
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C7H10N2OS
Molecular mass 170.233 g/mol

Propylthiouracil (PTU) or 6-n-propylthiouracil (PROP) is a thiouracil-derived drug used to treat hyperthyroidism (including Graves' disease) by decreasing the amount of thyroid hormone produced by the thyroid gland.[1] Its notable side effects include a risk of agranulocytosis and aplastic anemia.

On 3 June 2009, the FDA published an alert "notifying healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil."[2] As a result, propylthiouracil is no longer recommended in non-pregnant adults and in children as the front line antithyroid medication.[3]

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[3]


  • History 1
  • Mechanism of action 2
    • Central 2.1
    • Peripheral 2.2
  • Pharmacokinetics 3
  • Side effects 4
  • Propylthiouracil in pregnancy 5
  • Chemical synthesis 6
  • See also 7
  • References 8
  • External links 9


It was approved by the US Food and Drug Administration in 1947.

Mechanism of action


PTU inhibits the enzyme thyroperoxidase, which normally acts in thyroid hormone synthesis by oxidizing the anion iodide (I) to iodine (I0), facilitating iodine's addition to tyrosine residues on the hormone precursor thyroglobulin. This is one of the essential steps in the formation of thyroxine (T4).[4]

PTU does not inhibit the action of the sodium-dependent iodide transporter located on follicular cells' basolateral membranes. Inhibition of this step requires competitive inhibitors, such as perchlorate and thiocyanate.


PTU also acts by inhibiting the enzyme 5'-deiodinase (tetraiodothyronine 5' deiodinase), which converts T4 to the active form T3. (This is in contrast to methimazole, which shares propylthiouracil's central mechanism, but not its peripheral one.)


Administration is oral, with peak serum concentrations occurring in one hour, and actively concentrated to the thyroid gland. Depending on several patient variables, however, euthyroid status may not be achieved until 2–4 months after treatment initiation. Of note, the drug is approximately 70% protein-bound and significantly ionized at normal physiologic pH, while the antithyroid agent methimazole is substantially less protein bound. However both are equally transferred across the placenta.[5]

The plasma half-life is one hour and is not altered appreciably by the thyroid status of the patient. Due to the concentration in the thyroid, however, dosing intervals may last 8 hours or longer. Less than 10% of the drug is excreted unchanged, with the remaining fraction undergoing extensive hepatic metabolism via glucuronidation.

Side effects

One possible side effect is agranulocytosis,[6] a decrease of white blood cells in the blood. Symptoms and signs of agranulocytosis include infectious lesions of the throat, the gastrointestinal tract, and skin with an overall feeling of illness and fever. A decrease in blood platelets (thrombocytopenia) also may occur. Since platelets are important for the clotting of blood, thrombocytopenia may lead to problems with excessive bleeding. Side effects are suspected and the drug is sometimes discontinued if the patient complains of recurrent episodes of sore throat.

A more life-threatening side effect is sudden, severe, fulminant liver failure resulting in death or liver transplantation, which occurs in up to 1 in 10,000 people taking propylthiouracil. Unlike agranulocytosis which most commonly occurs in the first three months of therapy, this side effect may occur at any time during treatment.[3]

Propylthiouracil is generally well tolerated, with side effects occurring in one of every 100 patients. The most common side effects are related to the skin, and include rash, itching, hives, abnormal hair loss, and skin pigmentation. Other common side effects are swelling, nausea, vomiting, heartburn, loss of taste, joint or muscle aches, numbness and headache, allergic reactions, and hair whitening.

Propylthiouracil in pregnancy

Propylthiouracil is classified as methimazole is preferred to avoid the risk of liver complications from PTU in the mother.[3]

The primary effect on the fetus from transplacental passage of PTU is the production of a mild hypothyroidism when the drug is used close to term. This usually resolves within a few days without treatment. The hypothyroid state may be observed as a goiter in the newborn, and is the result of increased levels of fetal pituitary thyrotropin.[8] The incidence of fetal goiter after PTU treatment in reported cases is approximately 12%.[9]

Chemical synthesis

Propylthiouracil can be prepared from ethyl 3-oxohexanoate and thiourea.[10]

See also


  1. ^ Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N (June 2007). "Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease". The Journal of Clinical Endocrinology and Metabolism 92 (6): 2157–62.  
  2. ^ "Propylthiouracil (PTU)-Induced Liver Failure".  
  3. ^ a b c Bahn RS, Burch HS, Cooper DS, et al. (July 2009). "The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration". Thyroid 19 (7): 673–4.  
  4. ^ Boron, WF & Boulpaep, EL. 2005. Medical Physiology, Updated Edition. Elsevier Saunders, Philadelphia, PA
  5. ^ Abalovich M, Amino N, Barbour LA, et al. (August 2007). "Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline". J. Clin. Endocrinol. Metab. 92 (8 Suppl): S1–47.  
  6. ^ Cho YY, Shon HS, Yoon HD (December 2005). "Management of a pregnant patient with Graves' disease complicated by propylthiouracil induced agranulocytosis". The Korean journal of internal medicine 20 (4): 335–8.  
  7. ^ "propylthiouracil". Retrieved 2013-11-29. 
  8. ^ Fumarola, A; Di Fiore, A; Dainelli, M; Grani, G; Carbotta, G; Calvanese, A (Jun 2011). "Therapy of hyperthyroidism in pregnancy and breastfeeding.". Obstetrical & gynecological survey 66 (6): 378–85.  
  9. ^ "Propylthiouracil: Drug safety during pregnancy and breastfeeding". Retrieved 2013-11-29. 
  10. ^ Anderson, George W.; Halverstadt, I. F.; Miller, Wilbur H.; Roblin, Richard O. (1945). "Studies in Chemotherapy. X. Antithyroid Compounds. Synthesis of 5- and 6- Substituted 2-Thiouracils from β-Oxoesters and Thiourea". Journal of the American Chemical Society 67 (12): 2197–2200.  
  11. ^

External links

  • "Clinical Pharmacology Online Database". 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.